CLAIMS

What is claimed is:

1. Use of a composition comprising nanoparticles comprising a taxane and a carrier protein in the manufacture of a medicament for treating a proliferative disease in an individual, wherein the medicament is to be administered intravenously in combination with an effective amount of an inhibitor of DNA methyltransferase administered orally~~with an effective amount of at least one other agent that modifies the epigenetics in a cell~~.

~~2. The use according to claim 1, wherein said other agent is an inhibitor of histone deacetylase.~~

~~3. The use according to claim 2, wherein said other agent is vorinostat.~~

42. The use according to claim 1~~3~~, wherein the medicament is to be administered with a platinum-based agent.

~~5. The use according to claim 1, wherein said other agent is an inhibitor of DNA methyltransferase.~~

~~6~~3. The use according to claim 1~~5~~, wherein the other agent is azacitidine.

~~7~~4. The use according to claim 1~~5~~, wherein the other agent is decitabine.

~~8~~5. The use according to any one of claims 1-~~7~~4, wherein the proliferative disease is cancer.

~~9~~6. The use according to claim ~~8~~5, wherein the cancer is breast cancer.

~~10~~7. The use according to claim ~~9~~6, wherein the individual is negative for ER, PR, or HER2.

~~11~~8. The use according to claim ~~10~~7, wherein the individual is negative for ER, PR, and HER2.

~~12~~9. The use according to claim ~~8~~5, wherein the cancer is ovarian cancer.

~~13~~10. The use according to claim ~~8~~5, wherein the cancer is non-small lung cancer.

~~14~~11. The use according to claim ~~8~~5, wherein the cancer is endometrial cancer.

~~15~~12. The use according to claim ~~8~~5, wherein the cancer is cervical cancer.

~~16~~13. The use according to claim ~~8~~5, wherein the cancer is pancreatic cancer.

~~17~~14. The use according to claim ~~8~~5, wherein the cancer is melanoma.

~~18~~15. The use according to claim ~~8~~5, wherein the cancer is bladder cancer.

~~19~~16. The use according to claim ~~8~~5, wherein the cancer is head and neck cancer.

~~20~~17. The use according to any one of claims 1-~~19~~16, wherein the composition comprising nanoparticles comprising taxane and albumin and the other agent are to be administered simultaneously.

~~21~~18. The use according to any one of claims 1-~~19~~16, wherein the composition comprising nanoparticles of taxane and albumin and the other agent are to be administered sequentially.

~~22~~19. The use according to any one of claims 1-~~19~~16, wherein the composition comprising nanoparticles of taxane and albumin and the other agent are to be administered concurrently.

~~23~~20. The use according to any one of claims 1-~~22~~19, wherein the taxane is paclitaxel.

~~24~~21. The use according to any one of claims 1-~~23~~20, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

~~25~~22. The use according to any one of claims 1-~~24~~21, wherein the carrier protein is albumin.

~~26~~23. The use according to claim ~~25~~22, wherein the albumin is human serum albumin.

~~27~~24. The use according to claim ~~25~~22, wherein the albumin is human albumin.

~~28~~25. The use according to any of claim ~~25~~22-~~27~~24, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is about 1:1 to about 18:1.

~~29~~26. The use according to any of claims ~~25~~22-~~28~~25, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is about 1:1 to about 9:1.

~~30~~27. The use according to any one of claims 1-~~29~~26, wherein the individual is a human.

~~31~~28. The use according to any one of claims 1-~~30~~27, wherein the nanoparticles in the composition are to be administered intravenously.

~~32~~29. The use according to claim ~~31~~28, wherein the amount of taxane in the composition is between about 80 mg/m^2 to about 150 mg/m^2.

~~33~~30. The use according to claim ~~32~~29, wherein the amount of taxane in the composition is between about 100 mg/m^2 to about 125 mg/m^2.

~~34~~31. The use according to any one of claims 1-~~33~~30, wherein the other agent in the composition is to be administered orally.

~~35~~32. The use according to claim ~~34~~31, wherein the effective amount of the other agent in the composition is between about 80 mg to about 1000 mg.

~~36~~33. The use according to claim ~~35~~32, wherein the effective amount of the other agent in the composition is between about 100 mg to about 200 mg.

~~37~~34. A kit comprising: a) a composition comprising nanoparticles comprising a taxane and a carrier protein, and b) an effective amount of at least one other agent that inhibits DNA methyltransferase, wherein the inhibitor of DNA methyltransferase is suitable for oral administration~~modifies the epigenetics in a cell~~.

~~38. The kit according to claim 37, wherein said other agent is an inhibitor of histone deacetylase.~~

~~39. The kit according to claim 38, wherein said other agent is vorinostat.~~

~~40. The kit according to claim 37, wherein said other agent is an inhibitor of DNA methyltransferase.~~

~~41~~35. The kit according to claim ~~40~~34, wherein the other agent is azacitidine.

~~42~~36. The kit according to claim ~~40~~34, wherein the other agent is decitabine.

~~43~~37. The kit according to any one of claims ~~37~~34-~~42~~36, wherein the taxane is paclitaxel.

~~44~~38. The kit according to any one of claims ~~37~~34-~~43~~37, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

~~45~~39. The kit according to any one of claims ~~37~~34-~~44~~38, wherein the carrier protein is albumin.

~~46~~40. The kit according to claim ~~45~~39, wherein the albumin is human serum albumin.

~~47~~41. The kit according to claim ~~45~~39, wherein the albumin is human albumin.

~~48~~42. A medicine comprising: a) a composition comprising nanoparticles comprising a taxane and a carrier protein, and b) an effective amount of at least one other agent that inhibits DNA methyltransferase, wherein the inhibitor of DNA methyltransferase is suitable for oral administration~~modifies the epigenetics in a cell~~.

~~49. The medicine according to claim 48, wherein said other agent is an inhibitor of histone deacetylase.~~

~~50. The medicine according to claim 49, wherein said other agent is vorinostat.~~

~~51. The medicine according to claim 48, wherein said other agent is an inhibitor of DNA methyltransferase.~~

~~52~~43. The medicine according to claim ~~51~~42, wherein the other agent is azacitidine.

~~53~~44. The medicine according to claim ~~51~~42, wherein the other agent is decitabine.

~~54~~45. The medicine according to any one of claims ~~48~~42-~~53~~44, wherein the taxane is paclitaxel.

~~55~~46. The medicine according to any one of claims ~~48~~42-~~54~~45, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

~~56~~47. The medicine according to any one of claims ~~48~~42-~~55~~46, wherein the carrier protein is albumin.

~~57~~48. The medicine according to claim ~~56~~47, wherein the albumin is human serum albumin.

~~58~~49. The medicine according to claim ~~56~~47, wherein the albumin is human albumin.